Is elevated D-arabinitol above the lab range associated with yeast or fungal overgrowth?

D-arabinitol is a five-carbon sugar alcohol and a highly validated metabolic biomarker used to identify active yeast and fungal overgrowth, particularly Candida species.

Clinical evidence

• Diagnostic accuracy: Elevated urinary D-arabinitol, particularly when measured as a D-/L-arabinitol ratio, serves as a strong clinical indicator of fungal burden. In high-risk populations, its sensitivity and specificity for detecting invasive candidiasis frequently exceed 90%.
• Pathological thresholds: Values exceeding established pathological cutoffs—typically a D-/L-arabinitol ratio greater than 4.0 to 5.0, or absolute adult levels exceeding 55–60 mmol/mol creatinine—indicate significant fungal proliferation.

Mechanistic explanations

• Enantiomeric differences: Pathogenic Candida species produce the D-arabinitol enantiomer during carbohydrate fermentation. Conversely, human cells primarily produce and metabolize L-arabinitol, making an elevated ratio of D- to L-enantiomers highly specific to fungal activity.
• Species-specific production: The utility of this marker is limited to specific organisms; while common Candida species produce D-arabinitol, Candida glabrata and Candida krusei do not synthesize this metabolite, potentially resulting in false negatives.

Renal and clinical considerations

• Renal confounding: Renal dysfunction impairs metabolic clearance and independently elevates absolute serum and urinary D-arabinitol levels. To prevent false-positive interpretations—especially in older individuals with reduced kidney function—clinicians must rely on the D-/L-arabinitol ratio rather than absolute concentrations.
• Anatomical specificity: Elevated levels indicate systemic or heavy localized fungal burden, but the biomarker is not anatomically specific and does not definitively confirm localized gastrointestinal overgrowth.

Bottom line

• Urinary D-arabinitol is a scientifically supported biomarker for active Candida overgrowth, though clinicians must utilize the D-/L-arabinitol ratio to account for potential age-related renal confounding and pair results with clinical symptoms.